Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Prevotella copri Depletes IPA to Promote Breast Cancer Progr

    2026-05-16

    Prevotella copri-Mediated IPA Depletion Drives Breast Cancer Progression

    Study Background and Research Question

    Breast cancer remains the most prevalent malignancy among women globally, with rising incidence and mortality rates, especially in younger populations and regions with high human development indices. While genetic predispositions, such as BRCA1/2 mutations, are well-established risk factors, non-hereditary contributors—including gut microbiota composition—are increasingly recognized as pivotal in disease onset and progression (paper).

    The gut microbiome's functional and taxonomic shifts have been profiled in breast cancer, but the mechanistic causality linking specific microbial species to tumorigenesis remained unclear. This study probes whether and how Prevotella copri, a microbial species enriched in the gut of breast cancer patients, mechanistically promotes tumor progression via modulation of host metabolites, focusing on indole-3-pyruvic acid (IPA), a key tryptophan-derived intermediate with emerging roles in host physiology.

    Key Innovation from the Reference Study

    The principal scientific advance of this work is the identification of a causal, mechanistic link between gut microbiota composition—specifically Prevotella copri enrichment—and host cancer progression through metabolic depletion. The study demonstrates that excessive P. copri depletes systemic IPA, thereby disinhibiting the oncogenic UHRF1/AMPK axis, and provides in vivo evidence that this process promotes breast tumor growth (paper).

    This establishes IPA as an intrinsic, microbiota-sensitive anti-cancer metabolite, expanding the scope of microbiome-cancer interactions from immune modulation to direct metabolic regulation of tumorigenesis.

    Methods and Experimental Design Insights

    The study employed a combination of clinical, molecular, and animal model approaches:

    • Microbiome profiling: 16S rRNA sequencing was performed on fecal samples from breast cancer patients and healthy controls, revealing significant enrichment of Prevotella (especially P. copri) in patients' microbiota (paper).
    • In vivo tumor models: P. copri was orally administered to both specific pathogen-free (SPF) and germ-free mice, followed by breast cancer cell inoculation. Tumor growth was monitored longitudinally.
    • Metabolite quantitation: Targeted metabolomics assessed IPA levels in host tissues and serum, correlating their depletion with P. copri colonization.
    • Mechanistic assays: Molecular analyses (RNA/protein) evaluated UHRF1 and AMPK pathway activity in tumor tissues, linking IPA levels to these signaling nodes.

    This integrative design enabled direct testing of causality from microbiota composition through metabolite abundance to tumorigenic signaling and phenotype.

    Core Findings and Why They Matter

    Microbiome–Metabolite–Cancer Axis: The study found that P. copri is markedly enriched in the gut microbiota of breast cancer patients. Oral administration of P. copri to mice resulted in accelerated breast tumor growth and a sharp reduction in host IPA levels (paper).

    Mechanistic Insights: IPA, at physiological concentrations, was shown to directly suppress UHRF1 transcription. This suppression led to decreased nuclear UHRF1 and protein phosphatase 2A catalytic subunit (PP2A C), thereby inhibiting AMPK phosphorylation. Since AMPK is a central energy sensor and tumor suppressor, its inactivation creates a metabolic environment conducive to tumor progression. The reduction in IPA—driven by P. copri's consumption of tryptophan, the IPA precursor—thus tips the balance towards tumorigenesis via the UHRF1-mediated negative regulation of AMPK (paper).

    These findings position IPA as an endogenous anti-cancer factor, whose depletion by microbiota-derived metabolic competition constitutes a novel risk factor for breast cancer progression.

    Protocol Parameters

    • in vivo oral administration | 120 mg/kg (IPA) | breast cancer mouse models | demonstrated tumor growth inhibition | paper
    • in vitro cell assays | 500 μM (IPA) | human PBMC and tumor cell lines | supported for immunomodulation and signaling studies | product_spec
    • in vivo oral administration | 20 mg/kg/day (IPA) | arthritis rat models | demonstrates anti-inflammatory effects (context: immune modulation) | product_spec
    • in vitro cell viability/proliferation | 100–500 μM (IPA) | general | recommended starting range for mechanistic studies | workflow_recommendation

    Comparison with Existing Internal Articles

    While the reference study foregrounds the role of IPA depletion in breast cancer, complementary internal resources expand on IPA's broader physiological roles. For example, Cheng et al. (article) and related studies (article) demonstrate that IPA modulates immune balance in rheumatoid arthritis via activation of the aryl hydrocarbon receptor (AhR), highlighting its multifaceted influence on host immunity. In the plant biology domain, evidence from another article describes the IPA-mediated auxin (indole-3-acetic acid) biosynthetic pathway in fungi, establishing cross-kingdom relevance for this tryptophan metabolite.

    Notably, the reference study's mechanistic focus on the UHRF1/AMPK axis in breast cancer complements and extends these prior findings by linking microbiota-driven IPA depletion to cancer-specific signaling events, whereas previous work emphasized immune or plant hormone contexts.

    Limitations and Transferability

    Several limitations warrant consideration. First, while the study robustly demonstrates causality in mouse models, interspecies differences may modulate the relevance of these findings to human patients. The precise threshold of IPA depletion required to drive tumorigenic signaling, and the variability in microbiome composition across human populations, remain to be fully characterized. Additionally, the interplay between dietary tryptophan, microbiome metabolism, and systemic IPA levels is complex and not yet fully resolved.

    Transferability to clinical intervention is thus promising but requires further validation in human cohorts and mechanistic dissection of potential off-target effects.

    Research Support Resources

    To facilitate similar mechanistic and translational studies, researchers can utilize Indole-3-pyruvic acid (IPA, SKU C8759) from APExBIO, which is suitable for both in vitro and in vivo applications. Literature-backed dosing ranges (e.g., 500 μM for cell assays; 20–120 mg/kg in rodents) can be adapted according to experimental needs (paper, product_spec). For further insights into protocol design or cross-domain relevance—such as plant hormone and immune modulation—internal resources offer curated guidance (see this article).